Terrance P. Coyne, EVP & CFO at Royalty Pharma plc (RPRX), sold 69,582 shares at $46.67 ($3.3M) on 2026-03-02, disclosed to the SEC on 2026-03-04.
Open-market sale of $3.3M RPRX by EVP & CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.67 | 22,487 | $1.0M | 32.2% |
| 2 | $46.67 | 1,292 | $60K | 1.9% |
| 3 | $46.67 | 22,487 | $1.0M | 32.2% |
| 4 | $46.67 | 1,292 | $60K | 1.9% |
| 5 | $47.01 | 10,429 | $490K | 15.1% |
| 6 | $47.01 | 583 |
| $27K |
| 0.8% |
| 7 | $47.01 | 583 | $27K | 0.8% |
| 8 | $47.01 | 10,429 | $490K | 15.1% |
| Total | $46.78 avg | 69,582 | $3.3M | 100% |
| Filing → |
| RPRX | SELL | 2026-04-30 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-04-02 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-03-25 | $3.2M | — | Filing → |